Emergent Biosolutions, Inc. (EBS) News
Filter EBS News Items
EBS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EBS News Highlights
- EBS's 30 day story count now stands at 2.
- Over the past 12 days, the trend for EBS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EBS News From Around the Web
Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.
Why Is Icosavax (ICVX) Stock Up 46% Today?Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share. |
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023. |
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue EstimatesEmergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Emergent (EBS) Gets $75M BARDA Contract for Anthrax VaccineThe BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024. |
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). Deli |
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q FilingGAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC). Notices are routinely issued by the NYSE in such situations. Under the N |
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Call TranscriptEmergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Good afternoon, everyone. I am the operator for today’s call. Thank you for joining today as Emergent discusses the Operational and Financial Results for the Third Quarter of 2023. As is customary, today’s call is open to all participants and the call […] |
Emergent BioSolutions Inc. (NYSE:EBS) institutional owners may be pleased with recent gains after 83% loss over the past yearKey Insights Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence... |
Emergent BioSolutions (EBS) Q3 2023 Earnings Call TranscriptThank you for joining today as Emergent discusses the operational and financial results for the third quarter of 2023. As is customary, today's call is open to all participants and the call is being recorded and is copyrighted by Emergent BioSolutions. During today's call, Emergent may make projections and other forward-looking statements related to their business, future events, the prospects, or future performance. |
Emergent BioSolutions Reports Third Quarter 2023 Financial ResultsThird Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financial results reported include limited third quarter and year-to-date results, as well as selected balance sheet and cash flow in |